Our look is new. Our purpose is the same. Learn more about our brand evolution.
To coincide with World Rare Disease Day FSHD Patients across Europe say what they want from clinical trials Announcement by FSHD Europe FSHD Europe is pleased to publish the Lay […]
Participate in a research study on a muscle regenerating treatment for FSHD Vita Therapeutics is a cell engineering company harnessing the power of genetics to develop cellular medicines in the […]
Avidity Biosciences announced this week that it had received FDA Orphan Drug Designation for its experimental FSHD treatment, called AOC 1020. This does NOT mean the drug is now available […]
What does this mean for patients? An FDA Fast Track designation DOES NOT mean that the drug has been approved for use by patients. AOC 1020 is still a long […]
Patients are critical in helping to transform optimism into reality by Ken Kahtava, Chief Business Officer, FSHD Society Breakthroughs in FSHD research have identified the primary mechanism that causes FSHD. […]
